Please note: this site relies heavily on the use of javascript. Without a javascript-enabled browser, this site will not function correctly. Please enable javascript and reload the page, or switch to a different browser.
281  structures 260  species 4  interactions 5111  sequences 234  architectures

Family: Fibrinogen_C (PF00147)

Summary: Fibrinogen beta and gamma chains, C-terminal globular domain

Pfam includes annotations and additional family information from a range of different sources. These sources can be accessed via the tabs below.

This is the Wikipedia entry entitled "Fibrinogen". More...

Fibrinogen Edit Wikipedia article

fibrinogen alpha chain
Crystallographic structure of a fragment of human fibrin.[1]
Symbol FGA
Entrez 2243
HUGO 3661
OMIM 134820
RefSeq NM_000508
UniProt P02671
Other data
Locus Chr. 4 q28
fibrinogen beta chain
Symbol FGB
Entrez 2244
HUGO 3662
OMIM 134830
RefSeq NM_005141
UniProt P02675
Other data
Locus Chr. 4 q28
Fibrinogen gamma chain
Symbol FGG
Entrez 2266
HUGO 3694
OMIM 134850
RefSeq NM_021870
UniProt P02679
Other data
Locus Chr. 4 q28
Fibrinogen alpha/beta chain family
PDB 1m1j EBI.jpg
crystal structure of native chicken fibrinogen with two different bound ligands
Symbol Fib_alpha
Pfam PF08702
InterPro IPR012290
SCOP 1m1j
Fibrinogen alpha C domain
Symbol Fibrinogen_aC
Pfam PF12160
InterPro IPR021996
Fibrinogen beta and gamma chains, C-terminal globular domain
PDB 1m1j EBI.jpg
crystal structure of native chicken fibrinogen with two different bound ligands
Symbol Fibrinogen_C
Pfam PF00147
Pfam clan CL0422
InterPro IPR002181
SCOP 1fza

Fibrinogen (factor I) is a glycoprotein in vertebrates that helps in the formation of blood clots. It consists of a linear array of three nodules held together by a very thin thread which is estimated to have a diameter between 8 and 15 Angstrom (Å). The two end nodules are alike but the center one is slightly smaller. Measurements of shadow lengths indicate that nodule diameters are in the range 50 to 70 Å. The length of the dried molecule is 475 ± 25 Å.[2]

The fibrinogen molecule is a soluble, large, and complex 340 kDa plasma glycoprotein, that is converted by thrombin into fibrin during blood clot formation. It has a rod-like shape with dimensions of 9 × 47.5 × 6 nm and it shows a negative net charge at physiological pH (IP at pH 5.2).[3] Fibrinogen is synthesized in the liver by the hepatocytes.[3] The concentration of fibrinogen in the blood plasma is 200–400 mg/dL (normally measured using the Clauss method).

During normal blood coagulation, a coagulation cascade activates the zymogen prothrombin by converting it into the serine protease thrombin. Thrombin then converts the soluble fibrinogen into insoluble fibrin strands. These strands are then cross-linked by factor XIII to form a blood clot. FXIIIa stabilizes fibrin further by incorporation of the fibrinolysis inhibitors alpha-2-antiplasmin and TAFI (thrombin activatable fibrinolysis inhibitor, procarboxypeptidase B), and binding to several adhesive proteins of various cells.[4] Both the activation of factor XIII by thrombin and plasminogen activator (t-PA) are catalyzed by fibrin.[4] Fibrin specifically binds the activated coagulation factors factor Xa and thrombin and entraps them in the network of fibers, thus functioning as a temporary inhibitor of these enzymes, which stay active and can be released during fibrinolysis.[5] Research from 2011 has shown that fibrin plays a key role in the inflammatory response and development of rheumatoid arthritis.[6][citation needed]


In its natural form, fibrinogen can form bridges between platelets, by binding to their GpIIb/IIIa surface membrane proteins; however, its major function is as the precursor to fibrin.

Fibrinogen, the principal protein of vertebrate blood clotting, is a hexamer, containing two sets of three different chains (α, β, and γ), linked to each other by disulfide bonds. The N-terminal sections of these three chains contain the cysteines that participate in the cross-linking of the chains. The C-terminal parts of the α, β and γ chains contain a domain of about 225 amino-acid residues, which can function as a molecular recognition unit. In fibrinogen as well as in angiopoietin, this domain is implicated in protein-protein interactions. In lectins, such as mammalian ficolins and invertebrate tachylectin 5A, the fibrinogen C-terminal domain binds carbohydrates. On the fibrinogen α and β chains, there is a small peptide sequence (called a fibrinopeptide). These small peptides are what prevent fibrinogen from spontaneously forming polymers with itself.[7]

The conversion of fibrinogen to fibrin occurs in several steps. First, thrombin cleaves fibrinopeptide A and B located on the N-terminus of the fibrinogen alpha and beta chains respectively.[8] The resulting fibrin monomers polymerize end to end to from protofibrils, which in turn associate laterally to form fibrin fibers.[9] In a final step, the fibrin fibers associate to form the fibrin gel.[10]

Fibrinogen deficiency

Congenital fibrinogen deficiency (afibrinogenemia) or disturbed function of fibrinogen has been described in a few cases.[11]

It can lead to either bleeding or thromboembolic complications, or is clinically without pathological findings. More common are acquired deficiency stages that can be detected by laboratory tests in blood plasma or in whole blood by means of thrombelastometry.[12] Acquired deficiency is found after hemodilution, blood losses and/or consumption such as in trauma patients, during some phases of disseminated intravascular coagulation (DIC), and also in sepsis. In patients with fibrinogen deficiency, the correction of bleeding is possible by infusion of fresh frozen plasma (FFP), cryoprecipitate (a fibrinogen-rich plasma fraction) or by fibrinogen concentrates. There is increasing evidence that correction of fibrinogen deficiency or fibrinogen polymerization disorders is very important in patients with bleeding.[13]

Diagnostic use

Fibrinogen level can be measured in venous blood. Normal levels are about 1.5-3 g/L, depending on the method used. In typical circumstances, fibrinogen is measured in citrated plasma samples in the laboratory; however, the analysis of whole-blood samples by use of thromboelastometry (platelet function is inhibited with cytochalasin D) is also possible.[12] Higher levels are, amongst others, associated with cardiovascular disease (>3.43 g/L). It may be elevated in any form of inflammation, as it is an acute-phase protein; for example, it is especially apparent in human gingival tissue during the initial phase of periodontal disease.[14] Fibrinogen levels increase in pregnancy to an average of 4.5 g/l, compared to an average of 3 g/l in non-pregnant people.[15]

It is used in veterinary medicine as an inflammatory marker: In horses, a level above the normal range of 1.0-4.0 g/L suggests some degree of systemic inflammatory response.[citation needed]

Low levels of fibrinogen can indicate a systemic activation of the clotting system, with consumption of clotting factors faster than synthesis. This excessive clotting factor consumption condition is known as disseminated intravascular coagulation or "DIC." DIC can be difficult to diagnose, but a strong clue is low fibrinogen levels in the setting of prolonged clotting times (PT or aPTT), in the context of acute critical illness such as sepsis or trauma. Besides low fibrinogen level, fibrin polymerization disorders that can be induced by several factors, including plasma expanders, can also lead to severe bleeding problems.[12] Fibrin polymerization disorders can be detected by viscoelastic methods such as thrombelastometry.[12]

A fibrinogen uptake test or fibrinogen scan is a test that was formerly used to detect deep vein thrombosis. In this method, radioactively labeled fibrinogen, typically with radioiodine, is given which is incorporated in the thrombus. The thrombus can then be detected by scintigraphy.

Prognostic use

Fibrinogen level has been proposed as a predictor of hemorrhagic complications during catheter-directed trombolysis for acute or subacute peripheral native artery and arterial bypass occlusions.[16] However, a systematic review of the available literature until January 2016 found that the predictive value of plasma fibrinogen level for predicting hemorrhagic complications after catheter-directed thrombolysis is unproven.[17]


  1. ^ PDB: 1FZC​; Everse SJ, Spraggon G, Veerapandian L, Riley M, Doolittle RF (June 1998). "Crystal structure of fragment double-D from human fibrin with two different bound ligands". Biochemistry. 37 (24): 8637–42. doi:10.1021/bi9804129. PMID 9628725. 
  2. ^ Hall, Ph.D., Cecil E.; HENRY S. SLAYTER (18 August 1958). "The Fibrinogen Molecule: Its Size, Shape, and Mode of Polymerization" (PDF). The Journal of Biophysical and Biochemical Cytology. Plate 1. Cambridge, M: e Department of Biology, Massachusetts Institute of Technology. 5 (1): 11–6. doi:10.1083/jcb.5.1.11. PMC 2224630Freely accessible. PMID 13630928. Retrieved 24 May 2014. 
  3. ^ a b Marucco, Arianna; et al. (2013). "Interaction of fibrinogen and albumin with titanium dioxide nanoparticles of different crystalline phases" (PDF). Journal of Physics. Conference Series. 429 (1). Retrieved 24 May 2014. 
  4. ^ a b Muszbek L, Bagoly Z, Bereczky Z, Katona E (July 2008). "The involvement of blood coagulation factor XIII in fibrinolysis and thrombosis". Cardiovascular & Hematological Agents in Medicinal Chemistry. 6 (3): 190–205. doi:10.2174/187152508784871990. PMID 18673233. 
  5. ^ Kaiser B (2003). "DX-9065a, a direct inhibitor of factor Xa". Cardiovascular Drug Reviews. 21 (2): 91–104. doi:10.1111/j.1527-3466.2003.tb00108.x. PMID 12847561. 
  6. ^ Gilliam BE; Reed, Melinda R; Chauhan, Anil K; Dehlendorf, Amanda B; Moore, Terry L (2011). "Evidence of Fibrinogen as a Target of Citrullination in IgM Rheumatoid Factor-Positive Polyarticular Juvenile Idiopathic Arthritis". Pediatric Rheumatology. 9 (8): xx–xx. doi:10.1186/1546-0096-9-8. ISSN 1546-0096. PMC 3071779Freely accessible. PMID 21439056. 
  7. ^ PDOC00445 Fibrinogen C-terminal domain in PROSITE
  8. ^ Blombäck B, Hessel B, Hogg D, Therkildsen L (October 1978). "A two-step fibrinogen--fibrin transition in blood coagulation". Nature. 275 (5680): 501–5. doi:10.1038/275501a0. PMID 692730. 
  9. ^ Hermans J, McDonagh J (January 1982). "Fibrin: structure and interactions". Semin. Thromb. Hemost. 8 (1): 11–24. doi:10.1055/s-2007-1005039. PMID 7036348. 
  10. ^ Lorand L, Credo RB; John W. Fenton; Kenneth G. Mann (1977). "Thrombin and fibrin stabilization". In Mann KG; Lundblad RL; Fenton J. Chemistry and Biology of Thrombin. Ann Arbor, Mich: Ann Arbor Science Publishers. pp. 311–323. ISBN 0-250-40160-6. 
  11. ^ Acharya SS, Dimichele DM (November 2008). "Rare inherited disorders of fibrinogen". Haemophilia. 14 (6): 1151–8. doi:10.1111/j.1365-2516.2008.01831.x. PMID 19141154. 
  12. ^ a b c d Lang T, Johanning K, Metzler H, Piepenbrock S, Solomon C, Rahe-Meyer N, Tanaka KA (March 2009). "The effects of fibrinogen levels on thromboelastometric variables in the presence of thrombocytopenia". Anesthesia and Analgesia. 108 (3): 751–8. doi:10.1213/ane.0b013e3181966675. PMID 19224779. 
  13. ^ Fries D, Innerhofer P, Schobersberger W (April 2009). "Time for changing coagulation management in trauma-related massive bleeding". Current Opinion in Anaesthesiology. 22 (2): 267–74. doi:10.1097/ACO.0b013e32832678d9. PMID 19390253. 
  14. ^ Page RC, Schroeder HE (March 1976). "Pathogenesis of inflammatory periodontal disease. A summary of current work". Lab. Invest. 34 (3): 235–49. PMID 765622. 
  15. ^ Salvi, Vinita (2003). Medical and Surgical Diagnostic Disorders in Pregnancy. Jaypee Brothers Publishers. p. 5. ISBN 978-81-8061-090-5. 
  16. ^ "Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial". Annals of Surgery. 220 (3): 251–266; discussion 266–268. 1994-09-01. ISSN 0003-4932. PMC 1234376Freely accessible. PMID 8092895. 
  17. ^ Poorthuis, Michiel H. F.; Brand, Eelco C.; Hazenberg, Constantijn E. V. B.; Schutgens, Roger E. G.; Westerink, Jan; Moll, Frans L.; de Borst, Gert J. (2017-03-05). "Plasma fibrinogen level as a potential predictor of hemorrhagic complications after catheter-directed thrombolysis for peripheral arterial occlusions". Journal of Vascular Surgery. doi:10.1016/j.jvs.2016.11.025. ISSN 1097-6809. PMID 28274749. 

External links

This page is based on a Wikipedia article. The text is available under the Creative Commons Attribution/Share-Alike License.

This tab holds the annotation information that is stored in the Pfam database. As we move to using Wikipedia as our main source of annotation, the contents of this tab will be gradually replaced by the Wikipedia tab.

Fibrinogen beta and gamma chains, C-terminal globular domain Provide feedback

No Pfam abstract.

Literature references

  1. Spraggon G, Everse SJ, Doolittle RF , Nature 1997;389:455-462.: Crystal structures of fragment D from human fibrinogen and its crosslinked counterpart from fibrin. PUBMED:9333233 EPMC:9333233

Internal database links

External database links

This tab holds annotation information from the InterPro database.

InterPro entry IPR002181

Fibrinogen plays key roles in both blood clotting and platelet aggregation. During blood clot formation, the conversion of soluble fibrinogen to insoluble fibrin is triggered by thrombin, resulting in the polymerisation of fibrin, which forms a soft clot; this is then converted to a hard clot by factor XIIIA, which cross-links fibrin molecules. Platelet aggregation involves the binding of the platelet protein receptor integrin alpha(IIb)-beta(3) to the C-terminal D domain of fibrinogen [PUBMED:12799374]. In addition to platelet aggregation, platelet-fibrinogen interaction mediates both adhesion and fibrin clot retraction.

Fibrinogen occurs as a dimer, where each monomer is composed of three non-identical chains, alpha, beta and gamma, linked together by several disulphide bonds [PUBMED:11460466]. The N-terminals of all six chains come together to form the centre of the molecule (E domain), from which the monomers extend in opposite directions as coiled coils, followed by C-terminal globular domains (D domains). Therefore, the domain composition is: D-coil-E-coil-D. At each end, the C-terminal of the alpha chain extends beyond the D domain as a protuberance that is important for cross-linking the molecule.

During clot formation, the N-terminal fragments of the alpha and beta chains (within the E domain) in fibrinogen are cleaved by thrombin, releasing fibrinopeptides A and B, respectively, and producing fibrin. This cleavage results in the exposure of four binding sites on the E domain, each of which can bind to a D domain from different fibrin molecules. The binding of fibrin molecules produces a polymer consisting of a lattice network of fibrins that form a long, branching, flexible fibre [PUBMED:11593005, PUBMED:15837518]. Fibrin fibres interact with platelets to increase the size of the clot, as well as with several different proteins and cells, thereby promoting the inflammatory response and concentrating the cells required for wound repair at the site of damage.

This entry represents the C-terminal globular D domain of the alpha, beta and gamma chains. These domains are related to domains in other proteins: in the Parastichopus parvimensis (Sea cucumber) fibrogen-like FreP-A and FreP-B proteins; in the C terminus of the Drosophila scabrous protein that is involved in the regulation of neurogenesis, possibly through the inhibition of R8 cell differentiation; and in ficolin proteins, which display lectin activity towards N-acetylglucosamine through their fibrogen-like domains [PUBMED:12396010].

Domain organisation

Below is a listing of the unique domain organisations or architectures in which this domain is found. More...

Loading domain graphics...

Pfam Clan

This family is a member of clan Fibrinogen_C (CL0422), which has the following description:

This is a collection of families with C-terminal domains that are of similar structure.

The clan contains the following 2 members:

COLFI Fibrinogen_C


We store a range of different sequence alignments for families. As well as the seed alignment from which the family is built, we provide the full alignment, generated by searching the sequence database (reference proteomes) using the family HMM. We also generate alignments using four representative proteomes (RP) sets, the UniProtKB sequence database, the NCBI sequence database, and our metagenomics sequence database. More...

View options

We make a range of alignments for each Pfam-A family. You can see a description of each above. You can view these alignments in various ways but please note that some types of alignment are never generated while others may not be available for all families, most commonly because the alignments are too large to handle.

Representative proteomes UniProt
Jalview View  View  View  View  View  View  View  View  View 
HTML View                 
PP/heatmap 1                

1Cannot generate PP/Heatmap alignments for seeds; no PP data available

Key: ✓ available, x not generated, not available.

Format an alignment

Representative proteomes UniProt

Download options

We make all of our alignments available in Stockholm format. You can download them here as raw, plain text files or as gzip-compressed files.

Representative proteomes UniProt
Raw Stockholm Download   Download   Download   Download   Download   Download   Download   Download   Download  
Gzipped Download   Download   Download   Download   Download   Download   Download   Download   Download  

You can also download a FASTA format file containing the full-length sequences for all sequences in the full alignment.

HMM logo

HMM logos is one way of visualising profile HMMs. Logos provide a quick overview of the properties of an HMM in a graphical form. You can see a more detailed description of HMM logos and find out how you can interpret them here. More...


This page displays the phylogenetic tree for this family's seed alignment. We use FastTree to calculate neighbour join trees with a local bootstrap based on 100 resamples (shown next to the tree nodes). FastTree calculates approximately-maximum-likelihood phylogenetic trees from our seed alignment.

Note: You can also download the data file for the tree.

Curation and family details

This section shows the detailed information about the Pfam family. You can see the definitions of many of the terms in this section in the glossary and a fuller explanation of the scoring system that we use in the scores section of the help pages.

Curation View help on the curation process

Seed source: Prosite
Previous IDs: fibrinogen_C;
Type: Domain
Author: Sonnhammer ELL
Number in seed: 5
Number in full: 5111
Average length of the domain: 186.20 aa
Average identity of full alignment: 34 %
Average coverage of the sequence by the domain: 40.76 %

HMM information View help on HMM parameters

HMM build commands:
build method: hmmbuild -o /dev/null HMM SEED
search method: hmmsearch -Z 26740544 -E 1000 --cpu 4 HMM pfamseq
Model details:
Parameter Sequence Domain
Gathering cut-off 20.2 20.2
Trusted cut-off 20.2 20.2
Noise cut-off 20.1 20.1
Model length: 221
Family (HMM) version: 17
Download: download the raw HMM for this family

Species distribution

Sunburst controls


Weight segments by...

Change the size of the sunburst


Colour assignments

Archea Archea Eukaryota Eukaryota
Bacteria Bacteria Other sequences Other sequences
Viruses Viruses Unclassified Unclassified
Viroids Viroids Unclassified sequence Unclassified sequence


Align selected sequences to HMM

Generate a FASTA-format file

Clear selection

This visualisation provides a simple graphical representation of the distribution of this family across species. You can find the original interactive tree in the adjacent tab. More...

Loading sunburst data...

Tree controls


The tree shows the occurrence of this domain across different species. More...


Please note: for large trees this can take some time. While the tree is loading, you can safely switch away from this tab but if you browse away from the family page entirely, the tree will not be loaded.


There are 4 interactions for this family. More...

Fibrinogen_C Collagen Fib_alpha Fib_alpha


For those sequences which have a structure in the Protein DataBank, we use the mapping between UniProt, PDB and Pfam coordinate systems from the PDBe group, to allow us to map Pfam domains onto UniProt sequences and three-dimensional protein structures. The table below shows the structures on which the Fibrinogen_C domain has been found. There are 281 instances of this domain found in the PDB. Note that there may be multiple copies of the domain in a single PDB structure, since many structures contain multiple copies of the same protein seqence.

Loading structure mapping...